男性和女性膀胱癌的负担：生命损失年的分析。

The burden of bladder cancer in men and women: analysis of the years of life lost.

机构信息

Department of Urology, University of Rochester Medical Center, Rochester, NY, USA.

出版信息

BJU Int. 2012 Jan;109(1):57-62. doi: 10.1111/j.1464-410X.2011.10318.x. Epub 2011 Aug 23.

DOI:10.1111/j.1464-410X.2011.10318.x

PMID:21883817

Abstract

OBJECTIVE

To estimate the average loss in life expectancy (LE) due to bladder cancer (BC) in men and women in the USA.

PATIENTS AND METHODS

Cancer records for 51,528 patients diagnosed with BC during 1988-1997 were obtained from the Surveillance, Epidemiology, and End Results database. Potential follow-up ranged from 10 to 20 years (median 14 years). Loss in median LE at BC diagnosis was computed as the difference between expected median survival and observed median survival. Expected survival was calculated using two methods: method 1 used age, sex, and race-specific LE in the general population, method 2 used the hazard of death from non-BC causes in patients with BC (to account for past exposures and treatment-related toxicities not present in the general population).

RESULTS

During the study period, BC death occurred in 17% of men and 23% of women and non-BC death occurred in 53% of men and 47% of women. Using LE in the general population as the reference (method 1), loss in median LE at BC diagnosis was 3.9 years for men (33% of their potential remaining years of life) and 6.5 years for women (47% of their potential remaining years of life). Using non-BC-specific hazard as the reference (method 2), loss in median LE was 2.7 years for men (26% of their potential remaining years of life) and 4.1 years for women (36% of their potential remaining years of life).

CONCLUSION

Compared with men, women loose more years of life and a greater fraction of their life expectancy to BC.

摘要

目的

估计美国男性和女性膀胱癌（BC）导致的预期寿命平均损失。

患者和方法

从监测、流行病学和最终结果数据库中获取了 1988 年至 1997 年间诊断为 BC 的 51528 例患者的癌症记录。潜在随访时间为 10 至 20 年（中位数为 14 年）。BC 诊断时的中位预期寿命损失计算为预期中位生存与观察到的中位生存之间的差异。预期生存使用两种方法计算：方法 1 使用一般人群中年龄、性别和种族特异性的 LE，方法 2 使用 BC 患者非 BC 死亡的危险（以考虑过去的暴露和一般人群中不存在的治疗相关毒性）。

结果

在研究期间，男性中有 17%死于 BC，女性中有 23%死于 BC，男性中有 53%死于非 BC，女性中有 47%死于非 BC。使用一般人群中的 LE 作为参考（方法 1），BC 诊断时的中位 LE 损失为男性 3.9 年（占其潜在剩余寿命的 33%），女性 6.5 年（占其潜在剩余寿命的 47%）。使用非 BC 特异性危险作为参考（方法 2），男性的中位 LE 损失为 2.7 年（占其潜在剩余寿命的 26%），女性为 4.1 年（占其潜在剩余寿命的 36%）。